Background
EMAP-II is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues. Recombinant human EMAP-II is an 18.3 kDa protein consisting of 166 amino acid residues.
Specifications
Additional Names
Endothelial-Monocyte Activating Polypeptide II
Preparation
Biological activity was determined by the apoptotic effect on MCF - 7 cells using a concentration of 20 - 40 ng/ml.
Location
SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK
Source
E. coli
Reactivity
n/a
Tested Application
n/a
Storage
The lyophilized EMAP-II recombinant protein is stable for at least 2 years from date of receipt at -20ËšC. Reconstituted EMAP-II is stable for at least 3 months when stored in working aliquots with a carrier protein at -20ËšC. As with any protein, exposing EMAP-II recombinant protein to repeated freeze / thaw cycles is not recommended. When working with proteins care should be taken to keep recombinant protein at a cool and stable temperature.
Species Reactivity
n/a
Purity
Greater than 98% by SDS-PAGE gel and HPLC analyses.
Endotoxin level is less than 0.1 ng per μg (1EU/μg).
